Comparing surgery first versus chemotherapy first for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial compares two ways of treating advanced ovarian cancer: having surgery first, or having chemotherapy first followed by surgery. The goal is to see which approach improves outcomes for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has spread to the upper abdomen or beyond (stage IIIC or IV).
- Your cancer must not be a low-grade, mucinous, or borderline type.
- You must have enough healthy bone marrow, kidney, and liver function to safely receive chemotherapy and undergo surgery.
- You must be physically able to handle daily activities (performance status) and have a good surgical risk score (ASA 1 or 2).
- You must not have had any other cancer (except early-stage or non-invasive) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
This trial studies whether an additional treatment after surgery can help people with early-stage epithelial ovarian cancer live longer and stay well for more time. It is meant for patients who had a detailed staging operation and are able to start treatment within 8 weeks.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.